Form 4: Lexeo Therapeutics CLO Sells Shares for Tax Cover

Lexeo Therapeutics' Chief Legal Officer, Jenny Robertson, executed pre-planned transactions, acquiring shares and selling a portion to cover tax obligations from RSU vesting.

Summary

• Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, Inc. (LXEO), reported changes in her beneficial ownership.
• On October 15, 2025, she acquired 9,900 shares of Common Stock at a price of $0.
• On October 17, 2025, she sold 3,486 shares of Common Stock at a weighted average price of $8.935 per share.
• Also on October 17, 2025, she sold an additional 40 shares of Common Stock at a weighted average price of $9.561 per share.
• These sales were explicitly stated to cover tax obligations arising from the release of Restricted Stock Units (RSUs).
• Following these transactions, Ms. Robertson beneficially owns 68,930 shares of Common Stock, which includes 51,092 RSUs.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The transactions are largely routine, involving both an acquisition of shares and sales to cover tax obligations from RSU vesting. The use of a 10b5-1 plan and the stated purpose for sales mitigate any negative sentiment, suggesting a neutral to slightly positive outlook due to the underlying RSU vesting and share acquisition.

Positives

• The acquisition of 9,900 shares of Common Stock on October 15, 2025, at a price of $0, increases the reporting person's overall beneficial ownership.
• The sales were explicitly for covering tax obligations related to RSU vesting, indicating a non-discretionary, routine event rather than a bearish outlook.
• The transactions were conducted under a Rule 10b5-1(c) plan, demonstrating pre-planned and compliant insider trading practices.

Negatives

• A net reduction of 3,526 shares of directly owned common stock (3,486 + 40) occurred due to the sales, although this was for tax purposes.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as the transactions are routine for tax purposes and pre-planned, not signaling a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.
• Management: The Chief Legal Officer is managing her equity compensation in a standard, compliant manner.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically the acquisition of shares and subsequent sales to cover tax obligations related to RSU vesting, executed under a Rule 10b5-1 plan. Such transactions are common and do not typically reflect a change in the company's fundamental outlook or the insider's long-term confidence. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Lexeo Therapeutics, LXEO, Insider Transaction, Form 4, Stock Sale, RSU, Chief Legal Officer, Jenny Robertson, 10b5-1 Plan